Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905169 | 0.87 | HIF1A (0.54) | HIF1AALDH1A1KDM4EHPGDALOX15 | |
| SCHEMBL17269428 | 0.85 | HDAC3 (0.55) | HPGDALOX15HSD17B10MAPTLMNA | |
| SCHEMBL22721391 | 0.85 | GSK3B (0.56) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL28720693 | 0.84 | GSK3B (0.55) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL20543169 | 0.84 | GSK3B (0.55) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL28543600 | 0.84 | HIF1A (0.56) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL28002211 | 0.83 | GSK3B (0.51) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL3235361 | 0.83 | GSK3B (0.61) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL307839 | 0.82 | GSK3B (0.54) | GSK3BHIF1AALDH1A1KDM4EHPGD | |
| SCHEMBL28810975 | 0.81 | HIF1A (0.57) | GSK3BHIF1AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721566-B | Preparation method of 1- (4-morpholine phenyl) -1-butanone | 天津久日新材料股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-9957402-B2 | Compound, active energy ray curable composition, cured article thereof, printing ink, and inkjet recording ink | DIC CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9957402-B2 | Compound, active energy ray curable composition, cured article thereof, printing ink, and inkjet recording ink | DIC CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | DIC CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | DIC CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | DIC CORPORATION (JP) | 2017-06-01 | — | — | US | disclosed |
| CN-106414398-A | Compound, active energy ray-curable composition, cured product thereof, printing ink, and ink for inkjet recording | DIC株式会社 | 2017-02-15 | — | — | CN | disclosed |
| WO-2015174402-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | DIC株式会社 | 2015-11-19 | — | — | WO | disclosed |
| CN-103360272-A | Quaternary ammonium salt preparation method and application thereof | BEIJING INSIGHT HIGH TECHNOLOGY CO LTD | 2013-10-23 | — | — | CN | disclosed |
| EP-1468994-B1 | Process for preparing cyclic amine substituted phenyl-alkyl-ketones | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| EP-0805152-B1 | Cyclic amine substituted phenyl-alkyl-ketone and process for its preparation | CIBA SC HOLDING AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| EP-1468994-A1 | Process for preparing cyclic amine substituted phenyl-alkyl-ketones | Ciba SC Holding AG (CH) | 2004-10-20 | — | — | EP | disclosed |
| CN-1168700-C | Cyclic amine substd. phenylalkanone and preparing method thereof | ϣ�����⻯ѧ�عɹ�˾ | 2004-09-29 | — | — | CN | disclosed |
| CN-1072662-C | Cyclic amine-substituted phenylalkyl ketones and process for their preparation | CIBA SC HOLDING AG (CH) | 2001-10-10 | — | — | CN | disclosed |
| CN-1309116-A | Cyclic amine substd. phenylalkanone and preparing method thereof | CIBA SC HOLDING AG (CH) | 2001-08-22 | — | — | CN | disclosed |
| US-6191182-B1 | SUBJECTING P-HALOPHENYL ALKYL KETONE TO AMINOLYSIS WITH CYCLIC SECONDARY AMINE TO FORM CYCLIC AMINE-SUBSTITUTED PHENYL ALKYL KETONE; HALOGINATION AND REACTING WITH AMINE COMPOUND; STEVENS REARRANGEMENT UNDER BASIC CONDITION | CIBA SPECIALTY CHEMCIALS CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5977357-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICAL CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5795985-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| CN-1166487-A | Cyclic amine-substituted phenylalkyl ketones and process for their preparation | CIBA GEIGY AG (CH) | 1997-12-03 | — | — | CN | disclosed |
| EP-0805152-A2 | Cyclic amine substituted phenyl-alkyl-ketone and process for its preparation | Ciba SC Holding AG (CH) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152391-A1 | COMPOUND, ACTIVE ENERGY RAY CURABLE COMPOSITION, CURED ARTICLE THEREOF, PRINTING INK, AND INKJET RECORDING INK | CCNT1, EIF4A1, MARK1 | GSK3B 241/4885HIF1A 3341/4885ALDH1A1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.